Literature DB >> 3718530

Drug metabolism in cirrhosis. Selective changes in cytochrome P-450 isozymes in the choline-deficient rat model.

M Murray, L Zaluzny, G C Farrell.   

Abstract

The effect of a choline-deficient diet on microsomal cytochrome P-450 and mixed-function oxidase (MFO) activity was investigated in relation to the development of nutritional cirrhosis. In rats that received the choline-deficient diet for 28 weeks cirrhosis was evident macroscopically and histologically; control rats that received an identical diet supplemented with choline had normal livers. Microsomal cytochrome P-450 and cytochrome b5 were reduced in cirrhotic liver to 50% of control levels. Three MFO activities (ethylmorphine N-demethylase, aryl hydrocarbon hydroxylase and 7-ethoxycoumarin O-deethylase) were also reduced to 40-70% of control levels. However, the turnover number for the O-deethylation of 7-ethoxycoumarin was not reduced in cirrhotic liver. This finding suggested that certain drug oxidations may be selectively depressed in nutritional cirrhosis. To examine the possibility that selective changes in MFO activity may reflect the suppression of certain cytochrome P-450 isozymes, partially purified fractions of the cytochrome were prepared after solubilisation and hydrophobic affinity chromatography (on n-octylamino-Sepharose 4B) of cirrhotic and control liver microsomes. Analysis of these fractions by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and laser densitometry indicated that a protein band of apparent minimum molecular weight 50.5 kD was primarily affected in cirrhotic rat liver microsomes. Levels of two other bands (apparent minimum molecular weight 48 and 52.5 kD) appeared essentially unaltered. Additional electrophoretic studies, conducted under non-reduced conditions, indicated the haemoprotein nature of protein bands in the 48-55 kD region. These data strongly suggest that cirrhosis produced in rats by a choline-deficient diet is associated with selective decreases in oxidative drug metabolism and individual cytochrome P-450 isozymes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718530     DOI: 10.1016/0006-2952(86)90298-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  SUMOylation regulates cytochrome P450 2E1 expression and activity in alcoholic liver disease.

Authors:  Maria Lauda Tomasi; Komal Ramani; Minjung Ryoo; Carla Cossu; Andrea Floris; Ben J Murray; Ainhoa Iglesias-Ara; Ylenia Spissu; Nirmala Mavila
Journal:  FASEB J       Date:  2018-01-18       Impact factor: 5.191

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

Authors:  I A Leclercq; G C Farrell; J Field; D R Bell; F J Gonzalez; G R Robertson
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Differential regulation of endobiotic-oxidizing cytochromes P450 in vitamin A-deficient male rat liver.

Authors:  M Murray; R M Sefton; K D Croft; A M Butler
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress.

Authors:  Pei H Cui; Andy C Lee; Fanfan Zhou; Michael Murray
Journal:  Br J Pharmacol       Date:  2010-02-24       Impact factor: 8.739

7.  A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Patrick M Gillevet; Neeral R Patel; Vishwadeep Ahluwalia; Jason M Ridlon; Birgit Kettenmann; Christine M Schubert; Masoumeh Sikaroodi; Douglas M Heuman; Mary M E Crossey; Debulon E Bell; Philip B Hylemon; Panos P Fatouros; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2012-04-12       Impact factor: 3.584

8.  Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis.

Authors:  E Cantrill; M Murray; I Mehta; G C Farrell
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

9.  In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.

Authors:  Manoranjenni Chetty; Fabrizio d'Esposito; Wei V Zhang; John Glen; Glenys Dore; Zvijezdana Stankovic; Robert J Edwards; Iqbal Ramzan; Michael Murray
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.